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Abstract 
Background: The evasion of apoptosis through dysregulated Bcl‑2 family members is a hallmark of leukaemia stem 
cells (LSCs) in acute myeloid leukaemia (AML). Therefore, targeting Bcl‑2 with venetoclax has been suggested as an 
attractive strategy for inducing apoptosis in AML LSCs. However, the selective inhibition of Bcl‑2 in AML often leads to 
upregulation of Mcl‑1, another dominant anti‑apoptotic Bcl‑2 family protein conferring venetoclax resistance.
Methods: We assessed the combined effect of venetoclax and arsenic trioxide (ATO) on leukaemic cell viability, 
apoptosis, combination index, and cell cycle in the human LSC‑like KG1 and KG1a cells. The synergistic effect of vene‑
toclax and ATO on apoptosis was also examined in primary  CD34+ and  CD34+CD38− LSCs from the bone marrow 
(BM) of AML patients, and compared with those from healthy donors.
Results: Venetoclax efficiently impaired cell viability and dose‑dependently promoted apoptosis when combined 
with ATO; their synergism was aptly represented by the combination index. The combination of venetoclax and ATO 
impaired cell cycle progression by restricting cells within the sub‑G1 phase and facilitating caspase‑dependent apop‑
totic cell death associated with the loss of mitochondrial membrane potential, while sparing healthy BM haematopoi‑
etic stem cells. Mechanistically, ATO mitigated venetoclax‑induced upregulation of Mcl‑1 by the inhibition of AKT and 
ERK, along with activation of GSK‑3β. This led to the Mcl‑1 destabilisation, triggering Noxa and Bim to facilitate apop‑
tosis and the consequent activation of the apoptosis executioner protein Bak. Moreover, the combination promoted 
phosphorylation of ATM, Chk2, p38, and H2AX, indicating an active DNA damage response.
Conclusions: Our findings demonstrate the synergistic, preferential antileukaemic effects of venetoclax and ATO on 
LSCs, providing a rationale for preclinical and clinical trials by combining these agents already being used in clinical 
practice to treat acute leukaemia.
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Background
Acute myeloid leukaemia (AML) is a heterogeneous hae-
matological malignancy involving haematopoietic stem 
cells (HSCs) and progenitor cells [1, 2]. Although a sub-
stantial proportion of AML patients achieve a complete 
remission with intensive cytotoxic chemotherapy, most 
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patients succumb to disease relapse [1–5]. AML relapse 
is considered to originate from leukaemia stem cells 
(LSCs), which are metabolically quiescent, capable of 
self-renewal, and responsible for chemotherapy resist-
ance [6, 7]. Therefore, more effective therapeutic strate-
gies targeting LSCs are required to improve the cure rate 
in AML.
Bcl-2 protein is frequently overexpressed in AML LSCs 
[8]; this overexpression is associated with chemotherapy 
resistance, culminating in dismal clinical outcomes [9]. 
In this regard, development and clinical trials of Bcl-2 
inhibitors have been conducted during recent years [10]. 
Venetoclax (ABT-199) is a BH3 mimetic, which selec-
tively inhibits Bcl-2 and stabilises proapoptotic proteins 
[11]. It was shown that venetoclax can induce LSC cyto-
toxicity while largely sparing normal HSCs [12]. How-
ever, the biological and clinical actions of venetoclax 
employed as a single-agent have produced unsatisfactory 
results in AML [10]. Thus, the combination approach was 
developed, leading to approval for the use of venetoclax 
in combination with DNA methyltransferase inhibitors 
or low-dose cytarabine for elderly patients with newly 
diagnosed AML and those patients deemed unfit for 
conventional cytotoxic chemotherapy [13–17]. How-
ever, up to one-third of patients do not respond to these 
regimens [18, 19]. Besides, the majority of AML patients 
who achieve remission after receiving these combina-
tion therapies ultimately relapse, with a median dura-
tion of response of only about a year [18, 19]. Hence, 
there is an urgent requirement to elucidate the molecular 
mechanism underlying venetoclax resistance and develop 
novel combination strategies to target and overcome this 
resistance.
Mcl-1 is a critical anti-apoptotic protein that regulates 
cell survival in AML [20–22]. Mcl-1 upregulation coin-
cides with episodes of relapse in chemotherapy-treated 
AML, emphasising the role of Mcl-1 in the development 
of drug resistance [23, 24]. Furthermore, emerging evi-
dence suggests the upregulation of Mcl-1 protein as one 
of the mechanisms underlying acquired resistance to 
venetoclax treatment in AML [22–24]. Therefore, selec-
tive inhibitors of Mcl-1 are currently being investigated 
in preclinical and clinical studies on haematological 
malignancies, including AML [22]. However, the clinical 
development programme for a safe and selective Mcl-1 
inhibitor has proven challenging so far. The large size, 
high lipophilicity, poor pharmacokinetic profile, limited 
cell membrane permeability, and shallow binding groove 
on Mcl-1 are the major hurdles impeding the develop-
ment of Mcl-1 inhibitors [25]. Therefore, it is important 
to identify clinically available agents that interfere with 
Mcl-1 to augment the therapeutic efficacy of venetoclax 
in AML.
Arsenic trioxide (ATO) is a potent agent against acute 
promyelocytic leukaemia (APL) [26] and imparts a sig-
nificant survival benefit in patients with relapsed APL 
[27]. Furthermore, recently acquired evidence favours 
the use of ATO with all-trans retinoic acid (ATRA) over 
anthracycline-based therapy as a first-line treatment 
option in newly diagnosed APL patients [28]. The toxicity 
profile of the ATO and ATRA combination appeared to 
be mild, with minimal myelosuppression and manageable 
adverse effects [28]. APL cell death by ATO is triggered 
by the generation of intracellular reactive oxygen species 
and induction of DNA damage response [29]. Indeed, 
ATO activates the intrinsic apoptotic pathway by lower-
ing the mitochondrial membrane potential; additionally, 
ATO-induced apoptosis is associated with the downregu-
lation of Bcl-2 and activation of proapoptotic executioner 
protein Bax [30]. Notably, ATO downregulates Mcl-1 
expression in APL cells [31], although the underlying 
mechanism is not fully elucidated.
In the present study, we investigated whether the com-
bination of venetoclax and ATO efficiently promotes 
apoptosis in AML LSC-like cells. Using LSC-like cell 
lines, as well as  CD34+CD38− primary AML cells and 
bone marrow (BM) cells from healthy donors, we dem-
onstrated that the combination of venetoclax and ATO 
synergistically and selectively exhibits anti-AML activity 
in vitro, simultaneously sparing normal HSCs. We dem-
onstrated that venetoclax-induced Mcl-1 upregulation 
is mitigated by ATO in AML LSC-like cells and revealed 
that downregulation of increased Mcl-1 levels is associ-
ated with the activation of GSK-3β. Our findings support 
a strategy for developing an effective and safe non-chem-
otherapeutic–based AML treatment regimen using a suc-
cessful combination of venetoclax and ATO.
Methods
Cell lines and patient samples
This study was carried out in accordance with the Dec-
laration of Helsinki and approved by the Institutional 
Review Board of Severance Hospital (Yonsei University 
College of Medicine, Seoul, Republic of Korea; 4-2010-
0669). KG1 and KG1a human leukaemia cell lines were 
obtained from the American Type Culture Collection 
(Manassas, VA, USA). KG1 cells were cultured in Roswell 
Park Memorial Institute-1640 medium (Gibco, Thermo 
Fisher Scientific, Waltham, MA, USA), and KG1a cells 
were cultured in Iscove’s modified Dulbecco’s medium 
(Gibco). All media were supplemented with 10% foetal 
bovine serum, 100 U/mL penicillin, and 100 μg/mL strep-
tomycin (Gibco) at 37  °C in a humidified environment 
under 5%  CO2. Primary samples were obtained from 
the BM aspirates of AML patients at diagnosis (n = 4) 
and healthy donors who donated their BM aspirates 
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for allogeneic haematopoietic stem cell transplantation 
(HSCT) (n = 4). To minimise the confounding effects 
specific to cytogenetic and/or molecular abnormalities, 
we utilised primary AML blasts only from cytogenetically 
normal AML patients without recurrent mutations. The 
clinical characteristics of AML patients at diagnosis or at 
relapse are summarised in Additional file 1: Table S1, S2. 
BM mononuclear cells (BMMCs) were isolated by Ficoll–
Hypaque (GE Healthcare, Chicago, IL, USA) density gra-
dient centrifugation. The patient cohort was registered at 
ClinicalTrials.gov (NCT02344966), and all patients and 
healthy donors provided written informed consent.
Cell culture and treatment
A stock solution of venetoclax (Selleckchem, Houston, 
TX, USA) was prepared in dimethyl sulfoxide (DMSO), 
and serial dilutions were prepared in culture medium 
prior to each experiment. The final DMSO concentration 
was less than 0.2% (v/v) in all experiments. ATO  (As2O3, 
Sigma-Aldrich, St. Louis, MO, USA) was dissolved in 
1.65  M  NaOH at 5 ×  10−2  M  to form a stock solution. 
The maximum concentration of NaOH in culture did not 
influence the growth of these cell lines.  Logarithmically 
growing cells (1 ×  105 cells/mL) were exposed to different 
concentrations of venetoclax in the presence/absence of 
various concentrations of ATO. The pan-caspase inhibi-
tor z-VAD-fmk (R&D Systems, Minneapolis, MN, USA) 
was added to the cells 2 h prior to venetoclax and ATO 
treatment.
Reagents and antibodies
Rabbit polyclonal antibodies against caspase-9, cas-
pase-3, poly(ADP-ribose) polymerase (PARP), phos-
pho-p38, Mcl-1, phospho-Mcl-1 (T163), Bim, Bak, Bax, 
phospho-GSK-3β (S9), GSK-3β, phospho-AKT (S437), 
AKT, phospho-ERK (T202/Y204), phospho-ATR (S428), 
phospho-Chk1 (S317), phospho-Chk2 (T68), and p53 
were purchased from Cell Signaling Technology (Dan-
vers, MA, USA). The rabbit polyclonal antibody against 
Bcl-xL and mouse anti-Bcl-2 and anti-Noxa monoclonal 
antibodies were obtained from Santa Cruz Biotechnol-
ogy (Dallas, TX, USA). The rabbit polyclonal antibody 
against phospho-Mcl-1 (S159) was obtained from BioVi-
sion (Milpitas, CA, USA). The rabbit polyclonal antibody 
against phospho-ATM (S1981) and mouse anti-phos-
pho-H2AX (S139) monoclonal antibody were obtained 
from Abcam (Cambridge, UK). Horseradish peroxidase 
(HRP)-conjugated goat anti-rabbit IgG and HRP-con-
jugated goat anti-mouse IgG were from Cell Signaling 
Technology. The mouse anti-α–Tubulin monoclonal anti-
body was  obtained from Merck Millipore (Burlington‚ 
MA, USA).
Mcl‑1 overexpression by transient transfection
The generation of Mcl-1 plasmid pcDNA3.1-Mcl-1 
was described previously [32]. Briefly, a suspension 
of 2 ×  106 KG1a cells was transfected with 1  μg of 
pcDNA3.1 or pcDNA3.1-Mcl-1 using programme V-01 
of the Amaxa Nucleofector device (Lonza Cologne 
GmbH, Cologne, Germany) according to the manufac-
turer’s instructions. Immediately after electroporation, 
the cells were resuspended in complete medium and 
incubated at 37 °C in a humidified atmosphere contain-
ing 5%  CO2 for 48 h.
Assessment of cell viability
Cells were seeded in 96-well plates (1 ×  105  cells/mL) 
and incubated overnight before treatment. After 48 h of 
treatment with the indicated concentrations of veneto-
clax in the presence/absence of ATO, 10 μL of the Cell 
Counting Kit-8 solution (Dojindo Molecular Technolo-
gies, Rockville, MD, USA) was added to each well. After 
incubation for 4 h, the absorbance at 450 nm was meas-
ured with a microplate reader (VersaMax, Molecular 
Devices, San Jose, CA, USA).
Apoptosis assay
Apoptosis evaluation was performed by an Annexin 
V binding assay using LSR Fortessa flow cytometer 
(BD Biosciences, Franklin Lakes, NJ, USA). Cells were 
treated with various concentrations of venetoclax with 
or without ATO for 48 h and resuspended in Annexin V 
binding buffer. They were then incubated with Annexin 
V-FITC (BD Biosciences) and propidium iodide (PI) or 
7-AAD (Beckman Coulter, Brea, CA, USA) for 15 min 
before flow cytometry analysis. To examine the apopto-
sis in the  CD34+CD38− cell fraction, cells were stained 
with anti-CD34-APC (BD Biosciences), anti-CD38-PE 
(BD Biosciences), and 7-AAD (Beckman Coulter) for 
30  min. The labelled cells were subsequently resus-
pended in Annexin V binding buffer and incubated 
with Annexin V-FITC (BD Pharmingen) for 15  min 
before flow cytometry analysis. Data were analysed 
using the FACSuite software (BD Biosciences).
Cell cycle analysis
Following each treatment cycle, cells were harvested, 
washed twice with PBS, and fixed in 70% ethanol at 
− 20 °C for 16 h. The fixed cells were washed twice with 
PBS and stained with PI for 15 min at 37 °C. Analysis of 
cells with sub-G1, G0/G1, S, and G2/M DNA content 
was performed using 10,000 cells on an LSR Fortessa 
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flow cytometer (BD Biosciences). Data were analysed 
using the FACSuite software (BD Biosciences).
Combination index
The combination effect was evaluated via quantitative 
analysis of dose–effect relationships based on the Chou-
Talalay method as described previously [33]. A combina-
tion index (CI) value was calculated using the CalcuSyn 
software (Biosoft, San Francisco, CA, USA); CI < 1 was 
considered synergistic, CI = 1 was considered additive, 
and CI > 1 was considered antagonistic.
Analysis of mitochondrial membrane potential
The mitochondrial membrane potential (MMP) was 
monitored using  DiOC6, as described previously [34]. For 
each condition, 1 ×  106 cells were incubated with 1  mL 
of DePsipher solution (Trevigen, Gaithersburg, MD, 
USA), which uses a cationic dye (5,5′6,6′-tetrachloro-
1,1′,3,3′tetraethylbenzimidazolylcarbocyanine iodide). 
After incubation for 20 min at 37  °C in a 5%  CO2 incu-
bator, cells were washed with 1  mL of pre-warmed 1X 
Reaction Buffer with Stabiliser Solution and subse-
quently analysed using an LSR Fortessa flow cytom-
eter (488 nmargonlaser) and the FACSuite software (BD 
Biosciences).
Western blot analysis
For protein extraction, cells were lysed with a radioim-
munoprecipitation (RIPA) assay buffer (Thermo Fisher 
Scientific) supplemented with protease and phosphatase 
inhibitors (Roche, Basel, Switzerland). Cell lysates were 
centrifuged for 10  min at 4  °C and 13,000  rpm. Protein 
concentrations of the supernatants were quantitated 
using the detergent-insensitive Pierce BCA protein assay 
kit (Thermo Fisher Scientific). Lamni buffer was added 
to total protein lysates, and samples were denatured at 
95  °C for 5  min. Aliquots of each protein lysate (10  μg) 
were subjected to SDS-PAGE. After electrophoresis, pro-
teins were transferred to nitrocellulose membranes and 
blocked for 30  min with 5% bovine serum albumin in 
0.1% Tween 20 in TBS (TBST). Primary antibodies were 
incubated overnight at 4  °C. After washing with TBST, 
membranes were incubated with the secondary per-
oxidase-coupled antibody for 1  h at room temperature 
and washed with TBST. The blots were visualised using 
enhanced chemiluminescence substrates (GE Health-
care). α-Tubulin was used as a loading control.
Statistical analyses
All values are presented as mean ± standard deviation 
(s.d.). The statistical significance of differences between 
two groups was determined by the two-tailed unpaired 
t-test, one-way analysis of variance (ANOVA) followed 
by Tukey’s honest significant difference test with ranks 
for multiple-group comparison, or two-way ANOVA 
with Bonferroni post-hoc analysis. Statistical analyses 
were performed using GraphPad Prism 8 (GraphPad 
Software, San Diego, CA, USA). Statistical significance 
was considered at P < 0.05.
Results
The venetoclax and ATO combination synergistically 
promotes apoptosis in AML LSC‑like cells
To assess the combined antileukaemic effects of the 
venetoclax and ATO in AML LSC-like cells, we used the 
KG1 cell line, which is characterised by the high surface 
expression of CD34 but lacking CD38  (CD34+CD38−). 
The KG1a cell line, with similar phenotypic character-
istics, was also included in the present study. We first 
treated these two cell lines with various concentrations of 
venetoclax (0–1,000 μM) in the presence/absence of ATO 
(3 µM). After incubation for 48 h, cell viability, apopto-
sis, and cell-cycle distribution were examined using the 
respective methods described in "Methods". As shown 
in Fig.  1a, b, the decrease in the level of cell viability 
was minimal to modest with the single-agent treatment 
of increasing concentrations of venetoclax in KG1 and 
KG1a cells. However, venetoclax substantially impaired 
the viability of these cells in a dose-dependent manner, 
when treated in combination with ATO (Fig. 1a, b).
We then measured the proportion of apoptotic cells 
using Annexin V and PI co-staining and flow cytometry 
analysis in these cells following treatment with increas-
ing concentrations of venetoclax (0–1000  μM) in the 
presence/absence of ATO (3 µM). A consistent trend was 
noted, involving a significant rise in apoptosis rate with 
the combination of venetoclax and ATO in KG1 and 
KG1a cells; however, only a minimal to a modest degree 
of apoptosis was observed following venetoclax treat-
ment alone (Fig.  1c, d). A noteworthy observation was 
that the cell death-enhancing effects of ATO were evident 
even with the lower doses of venetoclax (Fig. 1c, d). The 
combination effect generated by venetoclax and ATO on 
apoptosis was further examined by quantitative analysis 
of the dose–effect relationships based on the Chou–Tala-
lay method [33]. As shown in Fig. 1e, f, there was a syn-
ergistic effect on apoptosis generated by the interaction 
between venetoclax and ATO; this was further indicated 
by CI values less than 1 in both KG1 and KG1a cells.
Further analysis of cell cycle distribution revealed that 
the proportion of cells in the sub-G1 phase was signifi-
cantly increased after the venetoclax and ATO combi-
nation treatment compared with either agent alone, 
indicating that the disrupted cell cycle caused by the 
combination treatment may be linked to the induction of 
apoptosis (Fig. 2a, b).
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Fig. 1 Venetoclax dose‑dependently impairs cell viability and synergistically promotes apoptosis in KG1 and KG1a cells when in combination with 
ATO. a, b, Assessment of cell viability in KG1 (a) and KG1a (b) cells treated with the indicated concentration of venetoclax (0–1,000 nM) with or 
without ATO (3 µM) for 48 h. Cell viability was assessed by measuring the absorbance at 450 nm after incubating the treated cells for 4 h with Cell 
Counting Kit‑8 solution (Dojindo). Values were obtained from three independent experiments, and horizontal bars indicate mean ± s.d. *P < 0.05 
versus respective control by two‑tailed Mann–Whitney U test. c, d, Summary data of the percentage of apoptotic fraction in KG1 (c) and KG1a 
(d) cells, as assessed by Annexin V and PI staining and flow cytometric analysis after treatment with the indicated concentration of venetoclax 
(0–1,000 nM) with or without ATO (3 µM) for 48 h. Values were obtained from three independent experiments, and horizontal bars indicate 
mean ± s.d. *P < 0.05 versus control treatment by two‑tailed Mann–Whitney U test. e, f, Combination index of apoptotic cells after treatment with 
venetoclax and ATO in KG1 (e) and KG1a (f) cells. Values were obtained by median dose–effect analysis, and each dot indicates the value obtained 
from six independent experiments
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The venetoclax and ATO combination preferentially 
induces apoptosis in primary  CD34+ AML cells 
while sparing HSCs from healthy donors
To further examine whether ATO effectively promotes 
the venetoclax-induced apoptosis in primary AML LSC-
like cells, we harvested diagnostic BMMCs or BMMCs 
at relapse from AML patients without any cytogenetic 
abnormalities. The clinical characteristics of the AML 
patients are summarised in Additional file 1: Table S1, S2. 
BMMCs from AML patients were treated with 100  nM 
of venetoclax in the presence/absence of 3  μM of ATO. 
After 48  h of incubation, the fraction of apoptotic cells 
was measured among the blast gate,  CD34+ blasts, and 
 CD34+CD38− cells using Annexin V and 7-AAD staining 
and flow cytometry analysis. Representative flow cyto-
metric plots of gated  CD34+CD38− primary AML cells 
after the single or combination treatment with veneto-
clax and ATO are shown in Fig. 3a and Additional file 2: 
Fig. S1.
With venetoclax treatment alone, the frequen-
cies of Annexin  V+7-AAD+ apoptotic cells in the 



























































































































Fig. 2 The combination of venetoclax and ATO disrupts the KG1 and KG1a cell cycles. a, b, Cell cycle analysis by flow cytometry after treatment 
with control (DMSO 0.1% v/v), venetoclax (200 nM), ATO (3 µM), or the combination of venetoclax (200 nM) and ATO (3 µM) for 48 h. Representative 
histograms of the cell cycles of the gated live KG1 and KG1a cells after treatment (a) and their summary data (b). Values were obtained from three 
independent experiments, and horizontal bars indicate mean ± s.d
Fig. 3 The venetoclax and ATO combination preferentially induces apoptosis of primary LSCs from AML patients while sparing healthy donor 
HSCs. a, b, Representative flow cytometric analysis (a) and summary data (b) of the percentage of Annexin  V+7‑AAD+ apoptotic cells after gating 
for  CD34+CD38− primary AML cells in the BMMCs of AML patients at diagnosis after treatment with venetoclax (100 nM), ATO (3 µM), or both in 
combination for 48 h in total mononuclear cells (b, far left), gated  CD34+ cells (b, middle), or  CD34+CD38− cells (b, far right). Values were obtained 
from two independent experiments of n = 4 patients, and horizontal bars indicate mean ± s.d. *P values versus control treatment by two‑tailed 
Mann–Whitney U test. n.s., not significant. c, d, Representative flow cytometric analysis (c) and summary data (d) of the percentage of Annexin 
 V+7‑AAD+ apoptotic cells after gating for  CD34+CD38− cells in the BMMCs of healthy donors following treatment with venetoclax (100 nM), ATO 
(3 µM), or both in combination for 48 h in total mononuclear cells (d, far left), gated  CD34+ cells (d, middle), or  CD34+CD38− cells (d, far right). 
Values were obtained from two independent experiments of n = 4 healthy donors, and horizontal bars indicate mean ± s.d. *P values versus control 
treatment by two‑tailed Mann–Whitney U test. n.s., not significant
(See figure on next page.)
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 CD34+CD38− blast population were 33.93 ± 9.13%, 
49.98 ± 9.31%, and 58.51 ± 6.42, respectively (Fig.  3b). 
After ATO treatment alone, the apoptotic cell frac-
tion was 11.54 ± 7.51%, 7.91 ± 6.79%, and 19.1 ± 12.3% 
in the mononuclear cell blast gate,  CD34+ blast, and 
 CD34+CD38− blast population, respectively (Fig.  3b). 
However, with the combination treatment of veneto-
clax and ATO, the apoptotic fraction was significantly 
increased to 68.00 ± 5.66% in the mononuclear cell 
blast gate (P = 0.0007 vs venetoclax alone; P < 0.0001 
b
BMMCs from AML patients (n = 4 patients)
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vs ATO alone) (Fig.  3b). The differences in the level 
of apoptosis remained significant when analyses were 
performed for gated  CD34+ cells and  CD34+CD38− 
LSC-like cells (for  CD34+ cells, P = 0.0031 vs veneto-
clax and P < 0.0001 vs ATO; for  CD34+CD38− blasts, 
P = 0.0002 vs venetoclax and P < 0.0001 vs ATO) 
(Fig. 3b). The augmented induction of apoptosis by the 
combination of venetoclax and ATO was observed not 
only in gated  CD34+CD38− blasts, but also in gated 
 CD34+CD38+ or  CD34− cells of BMMCs at AML 
diagnosis (Fig.  3a, b and Additional file  3: Fig. S2), 
in addition to the BMMCs of relapsed AML patients 
(Additional file 4: Fig. S3).
Interestingly, as depicted in the representative flow 
cytometric plots of gated  CD34+CD38− cells after the 
single or combination treatment with venetoclax and 
ATO in the BMMCs of healthy donors (Fig.  3c and 
Additional file 2: Fig. S1), the combined effect of these 
agents on apoptosis was minimal in  CD34+CD38− cells 
as well as in the gated blasts,  CD34+ cells of healthy 
BMMCs (Fig. 3d). These findings implied that the com-
bination of venetoclax and ATO promotes induction of 
apoptosis preferentially in bulk AML cells and LSC-like 
cells while sparing HSCs.
The venetoclax and ATO combination potentially activates 
the caspase‑dependent mitochondrial apoptotic pathway
We next evaluated the changes in caspase cleavage and 
MMP to unravel the mechanism of cell death involved 
in the combination of venetoclax and ATO in LSC-like 
cells. Compared with a single treatment, the combina-
tion of venetoclax and ATO resulted in an increase in 
the levels of cleaved caspase-9, cleaved caspase-3, and 
cleaved PARP (Fig. 4a).
To further investigate the cell death mechanism 
potentially triggered by the combination of venetoclax 
and ATO, MMP was analysed by flow cytometry using 
the  DiOC6 probe. The venetoclax and ATO combina-
tion robustly induced a higher degree of MMP depo-
larisation compared with the extent of depolarisation 
induced by a single treatment with either agent in both 
KG1 and KG1a cells (Fig.  4b). Next, apoptotic status 
was analysed after the preincubation of these cells with 
pan-caspase inhibitor z-VAD-fmk (20 μM) for 2 h. As 
shown in Fig. 4c, d, z-VAD-fmk preincubation signifi-
cantly alleviated apoptosis induction by combination 
treatment with venetoclax and ATO in both KG1 and 
KG1a cells. Collectively, these findings indicated that 
the synergistic increase in the rate of apoptosis by the 
venetoclax and ATO combination is, at least in part, 
attributable to the activation of the caspase-dependent 
mitochondrial apoptotic pathway.
Mcl‑1 protein is downregulated by adding ATO 
to venetoclax treatment in KG1 and KG1a cells
To elucidate the molecular mechanisms involved in the 
synergistic increase in apoptosis level with the combi-
nation of venetoclax and ATO, we next examined the 
effects of this combination on the Bcl-2 family members, 
which are critical regulators of apoptosis [9]. There were 
no apparent changes in the protein level of Bcl-2 follow-
ing treatment with venetoclax in the presence/absence of 
ATO for 48 h in KG1 and KG1a cells (Fig. 5a). However, 
cleaved Bcl-2 was generated after treatment with ATO 
alone or in combination with venetoclax in KG1a cells, 
which was not observed in KG1 cells (Fig.  5a), suggest-
ing the contextual differences between these cells with 
respect to the molecular alterations involving the cellular 
apoptosis machinery.
Next, we evaluated the changes in the Mcl-1 protein 
level. There was a noticeable elevation in the Mcl-1 pro-
tein level with venetoclax single treatment in both KG1 
and KG1a cells (Fig. 5a). However, when these cells were 
treated with the combination of venetoclax and ATO, 
Mcl-1 protein levels were substantially downregulated in 
both these cell types (Fig. 5a). Remarkably, alleviation of 
the venetoclax-induced upregulation of Mcl-1 by ATO 
addition was conspicuous in KG1a cells (Fig. 5a).
To further elucidate the mechanism of Mcl-1 protein 
downregulation, we investigated the levels of Mcl-1 phos-
phorylation at  Ser159 (p-Mcl-1  Ser159) as well as at  Thr163 
residue (p-Mcl-1  Thr163). In parallel with the down-
regulation of Mcl-1 protein, the level of p-Mcl-1  Ser159 
was increased, whereas the level of p-Mcl-1  Thr163 was 
decreased following the combination treatment of vene-
toclax and ATO in both KG1 and KG1a cells (Fig.  5a). 
However, the change in the protein expression level of 
another anti-apoptotic member, Bcl-xL, was minimal 
after the combination treatment or either agent alone 
(Fig. 5a).
Notably, the protein level of Noxa, which is antago-
nised by Mcl-1 [35], was elevated after venetoclax and 
ATO combination treatment in both KG1 and KG1a 
cells (Fig. 5b). Likewise, the increase in the proapoptotic 
protein level of Bim, which forms a complex with Mcl-1 
[9], was highest when these cells were treated with the 
combination of venetoclax and ATO (Fig.  5b). The pro-
tein level of Bak, which is a core regulator of mitochon-
drial outer membrane permeabilisation and apoptosis 
that is normally sequestered by Mcl-1 [9], was strongly 
induced upon combination treatment, especially in KG1a 
cells, while to a lesser extent with ATO single treatment 
(Fig. 5b). The change in the protein level of another proa-
poptotic effector Bax was minimal, implying that Bax 
may not be a major contributor to enhanced cell death 
with the venetoclax and ATO combination in these cells 
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(Fig.  5b). Taken together, these findings indicated that 
Noxa and Bim may be untethered from Mcl-1-mediated 
binding through downregulation of Mcl-1, leading to 
the increased induction of apoptosis associated with Bak 
activation.
The venetoclax and ATO combination activates GSK‑3β 
in KG1 and KG1a cells
Since GSK-3β activation promotes p-Mcl-1  Ser159 
leading to proteasomal degradation of Mcl-1 protein 
[9], we evaluated GSK-3β activity by measuring the 
level of GSK-3β phosphorylation at  Ser9 (p-GSK-3β 
 Ser9). Although the change in the total protein level 
of GSK-3β was minimal, the level of p-GSK-3β  Ser9 
was notably decreased after treatment with ATO. This 
was mediated by enhanced GSK-3β activity induced 
by adding ATO to venetoclax treatment in KG1 and 
KG1a cells (Fig. 5c). The phosphorylated form of AKT 
 (Ser473) was diminished without significant changes in 
the level of total AKT by the combination treatment in 
both these cell types (Fig. 5c). The level of phosphoryl-











































































Fig. 4 The combination of venetoclax and ATO promotes caspase‑dependent apoptosis in KG1 and KG1a cells. a, Representative western blot 
analysis of the indicated proteins in KG1 and KG1a cells treated with venetoclax (200 nM), ATO (3 µM), or both in combination for 48 h. Similar results 
were obtained from three independent experiments. b, Summary data of MMP disruption, as assessed by flow cytometry, using the DePsipher Kit 
(Trevigen) in KG1 and KG1a cells treated with venetoclax (200 nM), ATO (3 µM), or both in combination for 48 h. Values were obtained from three 
independent experiments, and horizontal bars indicate mean ± s.d. *P values versus control treatment by two‑tailed Mann–Whitney U test. n.s., 
not significant. c, d, Summary data of the percentage of apoptotic cells, as assessed by Annexin V/PI staining and flow cytometric analysis after 
treatment with or without the pan‑caspase inhibitor z‑VAD‑fmk (20 µM) for 2 h prior to the addition of venetoclax (200 nM), ATO (3 µM), or both 
in combination for 48 h in KG1 (c) and KG1a (d) cells. Values were obtained from three independent experiments, and horizontal bars indicate 
mean ± s.d. *P values versus control treatment with or without z‑VAD‑fmk by two‑tailed Mann–Whitney U test. n.s., not significant
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at the  Thr163 residue (p- Mcl-1  Thr163) and stabilises 
Mcl-1, was also reduced in KG1 and KG1a cells in 
response to treatment with the combination of vene-
toclax and ATO (Fig.  5c). These results signified that 
venetoclax-induced Mcl-1 upregulation is mitigated 
by ATO via GSK-3β activation-mediated increase in 
the level of p-Mcl-1  Ser159 and decrease in the level 
of p-Mcl-1  Thr163. This may subsequently lead to the 
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Fig. 5 The venetoclax and ATO combination downregulates Mcl‑1 through GSK‑3β activation in KG1 and KG1a cells. a–c, Representative western 
blot analysis of the indicated proteins in KG1 and KG1a cells treated with venetoclax (200 nM), ATO (3 µM), or both in combination for 48 h. Similar 
results were obtained from three independent experiments
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Ectopic Mcl‑1 overexpression alleviates the venetoclax 
and ATO combination‑induced apoptosis
To further elucidate the role of Mcl-1 downregulation 
in the venetoclax and ATO combination-induced syn-
ergistic cell death, Mcl-1 overexpression was ectopically 
induced in KG1a cells (Fig.  6a), as described in "Meth-
ods". Briefly, KG1a cells were transfected with pcDNA3.1 
control or pcDNA3.1-Mcl-1 vector, and the level of apop-
tosis was examined with the Annexin V and PI staining 
after the single or combined treatment with venetoclax 
and ATO (Fig. 6b). The proportion of apoptotic cells was 
significantly diminished after the combination treatment 
in KG1a cells upon Mcl-1 overexpression (52.80 ± 6.59%), 
compared with the combination treatment in control 
KG1a cells without Mcl-1 overexpression (72.50 ± 5.47%, 
P = 0.0286) (Fig. 6b,c). These findings indicate that down-
regulation of Mcl-1 is critically involved in the synergistic 
increase in the level of apoptosis in AML LSC-like cells 
treated with a combination of venetoclax and ATO.
Venetoclax and ATO combination triggers robust DNA 
damage response
The findings above led us to explore the changes in the 
level of proteins involved in the DNA damage response 
after venetoclax and ATO treatment alone or in combi-
nation in KG1 and KG1a cells. As shown in Fig.  7, the 
combination of venetoclax and ATO robustly increased 
the levels of p-ATM  (Ser1981) and p-H2AX  (Ser139) com-
pared with the single treatment of either agent alone. 
In parallel, Chk2 phosphorylation at  Thr68 residue was 
markedly augmented with the combination treatment 
(Fig.  7). Phosphorylation of p38 mitogen-activated pro-
tein kinase (MAPK) was also augmented with the com-
bined treatment of venetoclax and ATO compared with 
the treatment of either agent alone (Fig. 7), signifying the 
robust induction of apoptosis by the combination treat-
ment in these cells. However, compared with the phos-
phorylation of ATM and Chk2, the phosphorylation of 
ATR  (Ser428) and Chk1(Ser317) were modest following 
the combination treatment (Fig. 7). Changes in p53 pro-
tein expression levels were not apparent in both KG1 and 
KG1a cells (Fig. 7). Taken together, these findings implied 
that p53-independent DNA damage response, especially 
the p-ATM  (Ser1981) and p-Chk2  (Thr68) pathway, is asso-
ciated with enhanced induction of apoptosis by the com-
bination of venetoclax and ATO.
Discussion
In the present study, we demonstrated that a combina-
tion of venetoclax and ATO synergistically promotes 
apoptosis in LSC-like leukaemia cells and induces apop-
tosis preferentially in primary LSCs from AML patients, 
concomitantly sparing HSCs from healthy donors. We 
further revealed that ATO mitigates venetoclax-induced 
upregulation of Mcl-1. The synergistic effects of this 
venetoclax and ATO combination are mediated by 
attenuated AKT and ERK with GSK-3β activation, con-
sequently triggering Mcl-1 destabilisation and degrada-
tion, via the activation of caspase-dependent apoptotic 
cell death and untethering of Noxa and Bim from Mcl-1, 
and Bak activation, associated with a strong DNA dam-
age response (Fig. 8).
Better understanding of the mechanisms that mediate 
synergism between venetoclax and ATO in AML cells 
other than Mcl-1 is still needed. Although other mecha-
nisms, such as the alterations in the fatty acid metabo-
lism [36], mitochondrial oxidative phosphorylation [37], 
and electron transport chain complexes [38], may be 
involved in the synergistic interaction, Mcl-1 inhibition 
was evident to be importantly associated with the syn-
ergistic cell death in AML cells induced with venetoclax 
and ATO combination in this study. Therefore, our data 
reinforce the prevailing concept of Mcl-1 as an impor-
tant resistance factor to venetoclax and confirm prior 
studies delineating Mcl-1 as a mediator of the differen-
tial responsiveness to ATO between APL and non-APL 
cells [31]. It was proposed that ATO distinctly downregu-
lates Mcl-1 via GSK-3β activation in APL cells; however, 
this was not the case in non-APL cells, where the addi-
tional modulation of the Mcl-1 level was necessary to 
sensitise non-APL cells to ATO-induced apoptosis [31]. 
Supporting this notion, we revealed that ATO activates 
GSK-3β in KG1 and KG1a cells when combined with 
venetoclax, which was associated with attenuated AKT 
and enhanced phosphorylation of Mcl-1 at  Ser159, sub-
sequently leading to Mcl-1 degradation. We also showed 
that the combination reduces p-ERK levels and dimin-
ishes Mcl-1 phosphorylation at  Thr163, which is required 
for Mcl-1 stabilisation [39]. These results jointly indi-
cated that ATO-induced downregulation of the increased 
Mcl-1 level in venetoclax-treated KG1 and KG1a cells 
could occur via similar mechanisms to those employed in 
ATO-treated APL cells.
Venetoclax treatment combined with the direct inhi-
bition of Mcl-1 by a lentiviral BH3-expressing vector is 
efficacious in overcoming venetoclax resistance in xeno-
graft models of AML [40]. Moreover, the addition of the 
selective Mcl-1 inhibitor S63845 [41, 42], AMG 176, or 
AM-8621 [43] enhances the sensitivity to venetoclax in 
AML cell lines as well as in primary AML cells. Indeed, 
these synergistic effects are also observed in AML pro-
genitor cells [33]. However, similar to other anti-apop-
totic proteins of the Bcl-2 family, Mcl-1 plays a vital role 
in the survival of various cells of normal tissues, includ-
ing cardiac and hepatic cells [44, 45], pluripotent stem 
cells [46], and neurons [47]. The development of selective 
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Fig. 6 Mcl‑1 overexpression alleviates apoptosis induced by the combination of venetoclax and ATO in KG1a cells. a, Western blot analysis of 
indicated proteins in KG1a cells treated with venetoclax (200 nM), ATO (3 µM), or both in combination for 48 h after transfection with pcDNA3.1 
control or pcDNA3.1‑Mcl‑1 vector. b, c, Representative flow cytometric analysis (b) and summary data (c) of the percentage of Annexin  V+PI+ 
apoptotic cells in KG1a cells transfected with pcDNA3.1 control or pcDNA3.1‑Mcl‑1 vector after treatment with venetoclax (100 nM), ATO (3 µM), or 
both in combination for 48 h. Values were obtained from two independent experiments, and horizontal bars indicate mean ± s.d. *P values versus 
control treatment by two‑tailed Mann–Whitney U test. n.s., not significant
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Mcl-1 inhibitors is seriously hampered by safety concerns 
and technical drawbacks in targeting Mcl-1 [25]. There-
fore, these challenges require extensive validation of 
observed results before direct Mcl-1 inhibitors become 
easily accessible and applicable in routine clinical prac-
tice [22].
A range of compounds indirectly causes a decline in 
the cellular level of Mcl-1 and its key signalling mol-
ecules. XPO1-selective inhibitor selinexor [48, 49], 
autophagy inhibitor spautin-1 [50], tyrosine kinase 
inhibitor sorafenib [51, 52], survivin inhibitor YM155 
[53], and CDK9 inhibitors [54, 55] are the representative 
compounds. Furthermore, MAPK signalling regulation 
by p53 activation [56], inhibitors of Nedd8-activating 
enzyme [57], as well as MEK [58], MDM2 [59], glutami-
nase [60], and pan-RAF [61] inhibitors have also been 
shown to reduce the level of Mcl-1. Although preclinical 
studies have demonstrated these agents’ efficacy, only a 
few of them are being investigated in clinical trials. It is 
anticipated that there would be a prolonged period pre-
ceding the application of safe and tolerable modulators 
of Mcl-1. Hence, it is extremely crucial to identify readily 
available and clinically applicable agents that inhibit 
Mcl-1 to improve the therapeutic efficacy of venetoclax. 
In this regard, the venetoclax and ATO combination 
may serve as a feasible and safe option for treating AML 
patients, as they possess a relatively optimal tolerability 
profile and non-overlapping harmful effects [62].
It has been recently recognised that the combination 
of venetoclax and ATO induces apoptosis in NPM1-
mutated OCI-AML3 cells, which constitute the cell line 
inherently resistant to venetoclax [63]. OCI-AML3 cells 
express high levels of Mcl-1, which has been shown to be 
further upregulated upon treatment with venetoclax [56]. 
However, the NPM1 mutation in OCI-AML3 cells con-
fers sensitivity to ATO even in the absence of venetoclax 
[64], and the changes in the level of Mcl-1 underlying the 
proposed synergism have not yet been demonstrated. 
Our data support the synergistic antileukaemic effects 
of venetoclax and ATO and provide mechanistic insights 
that the synergism between venetoclax and ATO is medi-
ated via ATO-mediated Mcl-1 downregulation.
We demonstrated that the combination of veneto-
clax and ATO spares HSCs from healthy donors while 
concomitantly promoting apoptosis in LSC-like cells. 
Homeostasis of healthy HSCs is regulated by oxidative 
phosphorylation (OXPHOS)-driven regeneration and 
glycolysis-mediated quiescence [65]. This balance is dys-
regulated in AML LSCs, as LSCs preferentially depend 
on mitochondrial OXPHOS to a greater degree than 
on glycolysis [7]. Considering that ATO activates quies-
cent HSCs and LSCs [66], the simultaneous inhibition 
of increased mitochondrial OXPHOS by venetoclax and 
unleashing LSC quiescence by ATO could have coop-
eratively sensitised LSCs to the combination treatment 
while sparing healthy HSCs. Indeed, no appreciable 
therapeutic effects of ATO as a single-agent in non-APL 
AML cells have been demonstrated to date [40, 67, 68], 
where we also observed the modest induction of apopto-
sis by ATO treatment alone. Given that ATO is relatively 
safe and tolerable in the current clinical settings [69], our 
data may provide the rationale for future preclinical and 
clinical trials for prolonged infusion of ATO in combina-
tion with venetoclax, which may generate an opportunity 
to capture a larger proportion of leukaemic cells, includ-
ing LSCs, which asynchronously enter the S phase [66].
We highlighted the synergism between venetoclax and 
ATO in mutant p53-expressing KG1 and KG1a cell lines. 
There were minimal changes in p53 protein expression 
when these cells were treated with either venetoclax and 
ATO alone or in combination. Although p53 activation 
and Bcl-2 inhibition have been shown to reciprocally 
overcome resistance to each other in primary AML cells, 
at least in part, through the negative regulation of Mcl-1 
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Fig. 7 The venetoclax and ATO combination triggers robust DNA 
damage response. Representative western blot analysis of the 
indicated proteins in KG1 and KG1a cells treated with venetoclax 
(200 nM), ATO (3 µM), or both in combination for 48 h. Similar results 
were obtained from three independent experiments
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venetoclax and ATO combination treatment in promot-
ing apoptosis are efficacious irrespective of the p53 sta-
tus. Therefore, our study may provide an opportunity for 
improving outcomes in patients harbouring p53-mutated 
AML, which is marked by an extremely poor progno-
sis [2, 70]. Moreover, our proposed concept may not be 
limited to AML. Other haematological malignancies 
expressing high levels of both Bcl-2 and Mcl-1, such as 
multiple myeloma [71], may also benefit from the veneto-
clax and ATO combination, which needs to be validated 
in future research.
Conclusions
In summary, our study elucidates the synergism between 
venetoclax and ATO in promoting LSC apoptosis by 
inhibiting AKT and ERK, leading to GSK-3β activation 
and Mcl-1 destabilisation, which will support future pre-
clinical and clinical trials evaluating the suitability of this 
combination for treating AML. This finding may lead to 
exciting prospects for a chemotherapy-free approach, 
especially for AML patients who are vulnerable and not 
strong enough to undergo high-intensity chemotherapy.
Abbreviations
AML: Acute myeloid leukaemia; APL: Acute promyelocytic leukaemia; ATRA : 
All‑trans retinoic acid; BM: Bone marrow; BMMC: BM mononuclear cell; DMSO: 
Dimethyl sulfoxide; ATO: Arsenic trioxide; HSC: Haematopoietic stem cell; 
HSCT: Haematopoietic stem cell transplantation; LSC: Leukaemic stem cell; 
MAPK: Mitogen‑activated protein kinase; MMP: Mitochondrial membrane 
potential; OXPHOS: Oxidative phosphorylation; PARP: Poly(ADP‑ribose) poly‑
merase; PI: Propidium iodide; RIPA: Radioimmunoprecipitation; ROS: Reactive 
oxygen species.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s40164‑ 021‑ 00221‑6.
 Additional file 1: Table S1. Baseline patient characteristics of primary 
AML samples at diagnosis. Table S2. Patient characteristics of primary 
AML samples at relapse. 
Additional file 2: Fig. S1. The venetoclax and ATO combination preferen‑
tially induces apoptosis of primary LSCs from AML patients while sparing 
healthy donor HSCs. Representative flow cytometric analysis of the 
unstained control for Fig. 3 in the BMMCs of AML patients at diagnosis (left 
panel) or healthy donors (right panel). 
Additional file 3: Fig. S2. The venetoclax and ATO combination promotes 
apoptosis of gated  CD34+CD38+ or  CD34− primary LSCs from AML 
patients. Representative flow cytometric analysis of the percentage of 
Annexin  V+7‑AAD+ apoptotic cells after gating for  CD34+CD38+ (above 
panels) or  CD34− (below panel) primary AML cells in the BMMCs of AML 
patients at diagnosis after treatment with venetoclax (100 nM), ATO (3 
μM), or both in combination for 48 h. 
Additional file 4: Fig. S3. The venetoclax and ATO combination promotes 
apoptosis of primary LSCs from relapsed AML patients. a, b, Representative 
flow cytometric analysis (a‑c) and summary data (d) of the percentage 
of Annexin  V+7‑AAD+ apoptotic cells after gating for  CD34+CD38− (a), 
 CD34+CD38+ (b), or  CD34− (c) primary AML cells in the BMMCs of 
relapsed AML patients after treatment with venetoclax (100 nM), ATO (3 




























Fig. 8 Proposed mechanism of synergistic action between venetoclax and ATO. Schematic diagram depicting the synergism between venetoclax 
and ATO in LSC‑like leukaemia cells and primary LSCs. Bcl‑2 inhibition by venetoclax in LSC‑like leukaemia cells leads to the upregulation of Mcl‑1, 
which confers resistance to venetoclax. However, upon combination treatment with venetoclax and ATO, AKT is attenuated and subsequently 
impairs GSK‑3β phosphorylation at Ser9 and activates GSK‑3β. This leads to the phosphorylation of Mcl‑1 at Ser159, triggering Mcl‑1 degradation. 
The levels of Noxa and Bim, which are normally sequestered by Mcl‑1, are elevated upon Mcl‑1 degradation and promote caspase‑dependent 
apoptosis associated with Bak activation. In parallel, ERK downregulation attenuates Mcl‑1 phosphorylation at Thr163, leading to Mcl‑1 
destabilisation. The venetoclax and ATO combination also induces the phosphorylation of ATM at Ser1981 and Chk2 at Thr68, promoting cell cycle 
arrest associated with a robust DNA damage response and apoptosis
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gated  CD34+ cells (d, middle), or  CD34+CD38− cells (d, far right). Values 
were obtained from two independent experiments of n = 4 patients, and 
horizontal bars indicate mean ± s.d. *P values versus control treatment by 
two‑tailed Mann–Whitney U test.
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